Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Abstract

Administering 7.5 mg/kg Bev after induction did not improve outcome in extensive SCLC patients.

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

“…One of these trials involved in ziv-aflibercept plus CT versus CT [16]; two bevacizumab plus CT versus CT [17, 18]; six rh-Endostatin plus CT versus CT [19–24]; six thalidomide plus CT versus CT [25–30]; one vandetanib plus CT versus CT [31]. The populations were comparable with respect to demographics, clinical parameters, stage at initial diagnosis in different clinical settings.…”

“…These results were summarized in Table 1. Among these 16 trials, two were phase III clinical trials [29, 30]; one phase II- III trial [18]; four phase II trials [16, 17, 19, 31] while nine studies did not mention a trial phase [20–28]. Outcomes included ORR, OS, PFS and severe adverse events (AEs, Grade≥3).…”

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer

“…In terms of adverse events, there was a high rate of severe phlebitis. Several studies have reported that bevacizumab has enhanced the toxicity and increased the activity of another agent in a combination regimen (22,23). Bevacizumab targets VEGF and alters tumor vessel physiology, thereby increasing intratumoral drug uptake (24,25).…”

Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience

“…In a recent randomized phase II/III trial it was reported that Bev alone after induction chemotherapy did not improve outcome in ED-SCLC patients. 21 Recent studies have been conducted to investigate innovative agents combined with chemotherapy in patients with ED-SCLC. However, specifically, no significant improvement in response rates, PFS, and OS were reported with chemotherapy with rh-endostatin, with carboplatin/E with the small-molecule B-cell lymphoma 2 (Bcl-2) inhibitor obatoclax, with P and amrubicin, nor with platinum-based chemotherapy and the sarcoma-kinase inhibitor saracatinib.…”